Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

OMED $18.08 0.9200 +5.36%
GLYC $7.80 0.3000 +4.00%
RNN $0.73 0.0268 +3.79%
XLRN $24.92 0.7100 +2.93%
MEIP $6.91 0.1800 +2.67%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

THLD $3.97 -0.5000 -11.19%
CYTK $3.81 -0.3300 -7.97%
CNDO $1.80 -0.1500 -7.69%
CERU $3.61 -0.3000 -7.67%
ONTX $4.33 -0.3500 -7.48%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Next > | Last >>

Molecular Study Confirms 4 Different HER2+ Breast Cancer Subtypes

(VHIO [Barcelona, Spain]) Sept 9, 2014 - Latest research at VHIO confirms 4 subgroups of HER2+ breast cancer with different molecular characteristics.
read press release 

CNIO Successfully Completes Its First Clinical Trial on HER-2-Negative Breast Cancer with Nintedanib

(CNIO [Madrid, Spain]) Sept 9, 2014 - The experimental drug nintedanib, combined with standard chemotherapy with paclitaxel, causes a total remission of tumours in 50% of patients suffering from early HER-2-negative breast cancer, the most common type of breast cancer.
read press release 

Association of Community Cancer Centers’ 2014 Survey: Cancer Programs Are Taking Charge, Developing Own Guidelines to Track and Measure Quality

(ACCC) Sept 10, 2014 - Results from the Association of Community Cancer Centers’ (ACCC) recently released annual Trends in Cancer Programs survey reveal a compelling new trend among cancer programs—an increasing number are proactively developing their own guidelines to help measure and track the quality of care provided, rather than waiting to be told what to do by payers.
read press release 

FDA Staff: Novo Nordisk Drug Liraglutide Effective for Obesity

(MSN Money/Reuters) Sept 9, 2014 - Novo Nordisk's drug liraglutide appears effective in treating obesity, according to a preliminary assessment by reviewers at the U.S. Food and Drug Administration released on Tuesday.
read article 

U.S. Widens Program to Dispose of Prescription Drugs

(Reuters) Sept 8, 2014 - Americans will be able to dispose of unused prescription drugs at more sites under a Drug Enforcement Administration rule announced on Monday aimed at curbing rising drug addiction and abuse.
read article 

FDA Advisory Panel Calls for Sunscreen Safety Testing

(Medscape Medical News) Sept 8, 2014 - An advisory committee has endorsed new safety testing standards proposed by the US Food and Drug Administration (FDA) for sunscreen ingredients, adding that even more action may be needed to ensure product safety.
read article (free registration required) 

Federal Trade Commission Sues AbbVie, Other Drug Companies

(Wall Street Journal) Sept 9, 2014 - The Federal Trade Commission on Monday sued AbbVie and other drug companies over allegations they unlawfully sought to delay generic competition for AbbVie's blockbuster testosterone-replacement drug.
read article (paid subscription required) 

Doctors’ Magical Thinking About Conflicts of Interest

(New York Times/The Upshot blog) Sept 8, 2014 - When the Food and Drug Administration creates an advisory committee to help it decide whether to approve drugs, it often asks academic physicians to serve on the committee as external experts. This is supposed to help the committee render judgments that are unbiased and scientific.
read press release 

2014 Chabner Colloquium Focuses on Collaboration in Cancer Trials

(PRWeb) Sept 9, 2014 - Registration is now open for the Society for Translational Oncology (STO) 2014 Chabner Colloquium: Collaboration in Cancer Trials.
read press release 

Public-private Partnership Funds $11.5M in Biophysics Cancer Research

(NSF) Sept 8, 2014 - A new public-private partnership between the National Science Foundation (NSF), National Cancer Institute (NCI), Stand Up To Cancer (SU2C) and The V Foundation for Cancer Research is committing $11.5 million towards transformational, theoretical biophysics that could have a significant impact on cancer research and treatment.
read press release 

Rutgers Receives $10 Million Donation for Cancer Research

( Sept 9, 2014 - Rutgers University has received a $10 million anonymous grant to help its scientists discover targeted therapies for hard-to-treat cancers.
read article 

ASCO Holds Town Halls on Payment Reform Model, Invites Member Feedback

(ASCO in Action) Sept 5, 2014 - ASCO recently held town hall meetings in Boston, Chicago, and Seattle to discuss the society’s payment reform model with members across the country.
read article 

ASCO Responds to Proposed Rules on 2015 Medicare Physician Fee Schedule and 2015 Hospital Outpatient Prospective Payment System

(ASCO in Action) Sept 5, 2014 - On September 2, 2014, ASCO submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding its proposed rules on the 2015 Medicare Physician Fee Schedule (MPFS)—including the Open Payments Program—and the 2015 Hospital Outpatient Prospective Payment System (HOPPS).
read article 

Biodesix Receives Highmark Blue Cross Blue Shield Coverage for VeriStrat Test

(4-traders) Sept 9, 2014 - Biodesix, Inc. today announced that its VeriStrat® test received a positive coverage decision from Highmark Inc., a Blue Cross Blue Shield (BCBS) affiliate organization and one of the largest insurance companies in the United States.
read article 

OPKO Licensee TESARO Submits New Drug Application For Rolapitant

(TheStreet) Sept 8, 2014 - OPKO Health, Inc., reported that its licensee, TESARO, Inc., has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV).
read article 

Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm. Co.

(Yahoo! Finance) Sept 9, 2014 - Spectrum Pharmaceuticals today announced the Phase 3 Go/No-Go decision for SPI-2012, its long acting Granulocyte Stimulating Factor (GCSF), and is planning for the start of Phase 3 clinical trials next year.
read article 

AACR Issues Policy Statement to Urge FDA to Provide Oversight of High Risk Laboratory Developed Tests to Protect Patient Safety and Product Innovation

(AACR) Sept 9, 2014 - AACR issued a policy statement that underscores the importance of safe, accurate, and effective diagnostic tests by recommending that the FDA begin to actively exert its authority to regulate high-risk laboratory developed tests (LDTs) that are being utilized by physicians to make treatment decisions, including the tailoring of an individual's cancer treatment regimen.
read press release 

CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Ifosfamide/Mesna as First-Line Treatment in Patients with Advanced Sarcomas

(CytRx) Sept 9, 2014 - CytRx Corporation today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus ifosfamide/mesna as a first-line treatment in subjects with various sarcomas.
read corporate press release 

Antifungal's Lower Side Effects Hold Promise

(MedPage Today) Sept 8, 2014 - An investigational antifungal drug had fewer side effects than an existing medication but was equally effective in cancer patients with an invasive mold infection, researchers reported.
read article (free registration required) 

University of Miami Collaborative Study Finds New Approach for Treating Esophageal Cancer

(University of Miami) Sept 9, 2014 - Drawing on their clinical and scientific experience, researchers at the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center have identified a new strategy for attacking esophageal adenocarcinoma (EAC), one of the most deadly forms of cancer.
read article 

Penn Team Finds Ovarian Cancer Oncogene in "Junk DNA"

(Penn Medicine) Sept 8, 2014 - Over the years researchers have made tremendous strides in the understanding and treatment of cancer by searching genomes for links between genetic alterations and disease.
read press release 

Watchful Waiting May Not Be Best for Black Men With Prostate Cancer

(U.S. News & World Report/HealthDay News) Sept 8, 2014 - Monitoring early stage prostate cancer instead of treating it may not be appropriate for all patients, especially black men, a new study indicates.
read article 

Low Free Testosterone Predicts Prostate Cancer Reclassification

(medwireNews) Sept 8, 2014 - Lower levels of free testosterone predict an increased likelihood of disease reclassification in men with prostate cancer, researchers report.
read article 

Radiation Therapy with Concurrent Chemotherapy After Surgery Is an Effective Treatment for Patients with High-risk Endometrial Cancer

(ASTRO) Sept 9, 2014 - Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for patients with high-risk endometrial cancer, according to a new study.
read press release 

Bone Cancer Surgical Team Sees Success in New Application of Surgical Aid

(Dartmouth-Hitchcock) Sept 8, 2014 - An ortho-oncology team at Dartmouth-Hitchcock Norris Cotton Cancer Center successfully adapted a shoulder surgical aid (the Spider Limb Positioner) to conduct a left hip disarticulation on a melanoma patient as described in a case report published online in Medical Devices.
read press release